TCGA-H7-A76A-01A-51R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.430
- COAGULATION+0.300
- INTERFERON_GAMMA_RESPONSE+0.280
- COMPLEMENT+0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.240
- IL6_JAK_STAT3_SIGNALING+0.230
- INFLAMMATORY_RESPONSE+0.230
- PANCREAS_BETA_CELLS+0.210
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.190
- ANGIOGENESIS+0.170
Top 10 suppressed
- PROTEIN_SECRETION-0.500
- MYC_TARGETS_V2-0.490
- MYC_TARGETS_V1-0.480
- G2M_CHECKPOINT-0.460
- MITOTIC_SPINDLE-0.430
- E2F_TARGETS-0.340
- MTORC1_SIGNALING-0.340
- ANDROGEN_RESPONSE-0.310
- TGF_BETA_SIGNALING-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f426318a-9c1a-4476-a087-2b3a84096f5c | — | — | 0.896 |
| 2 | SRR5088872 | — | — | 0.883 |
| 3 | TCGA-85-A513-01A-12R-A26W-07 | — | cohortA1 | 0.875 |
| 4 | f2903ac6-88e3-4653-a966-ab593fba51bf | — | — | 0.875 |
| 5 | TCGA-5L-AAT1-01A-12R-A41B-07 | — | A | 0.873 |
| 6 | TCGA-FD-A43U-01A-11R-A23W-07 | — | — | 0.871 |
| 7 | 3d89c16f-8045-4861-a82c-9f4624292284 | — | — | 0.869 |
| 8 | SRR1472301 | GTEX | — | 0.868 |
| 9 | TCGA-A2-A0CR-01A-11R-A22K-07 | — | B | 0.864 |
| 10 | 2d8d97e6-b599-4444-8e11-73adb55be0be | — | — | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.080 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.060 | Inavolisib | — uncovered |